Close

Immune Design starts dosing patients in Phase I study of LV305 immuno-oncology agent

News
Typography

US-based Immune Design has started dosing patients in a Phase I clinical study of LV305, an immuno-oncology investigational agent from its DCVex lentiviral vector platform to treat patients with locally advanced, relapsed, or metastatic breast cancer, melanoma, non-small cell lung cancer, ovarian cancer or sarcoma.

The company is focused on the development of novel immune-based therapies for cancer and other chronic conditions.

A total of 36 patients at several clinical centres in the US will be enrolled in the open label, multi-centre Phase I study, which is designed to assess the safety, tolerability and immunogenicity of LV305 in these patients.

"The advancement of novel immuno-oncology agents such as LV305 that induce a tumour-specific in-vivo T-cell response holds promise for the development of new and targeted approaches to cancer treatment."

Fred Hutchinson Cancer Research Center principal investigator Seth Pollack said: "The advancement of novel immuno-oncology agents such as LV305 that induce a tumour-specific in-vivo T-cell response holds promise for the development of new and targeted approaches to cancer treatment."

Immune Design president and chief executive officer Carlos Paya said: "LV305 is an integral part of our prime-boost strategy that is designed to provide a superior approach to fighting cancer.

"Data from the trial will include immunogenicity and initial indications of efficacy, and is intended to support the combination of LV305 with a second proprietary agent, G305, into our prime-boost strategy known as CMB305. We intend to commence a Phase 1 trial for CMB by the end of 2014."

Generated from the company's DCVex platform, LV305 is designed to activate the immune system through the in-vivo generation of cytotoxic T cells (CTLs) initially against a specific tumour-associated antigen, NY-ESO-1.

The company said that preclinical tests have showed the ability of LV305 to reduce tumour growth of NY- ESO-1-expressing tumours, increase production of antigen-specific CD8 cells, and significantly improve the survival of tumour-bearing animals.

LV305 is the first step in the company's new prime-boost approach to immuno-oncology, which includes combination with G305, generated from the GLAAS platform, to expand CTLs and potentially generate a potent, durable immune response.

Subscribe to our Newsletter
captcha 
Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok